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Mouhab Ayas,1 Amal Al-Seraihi,1 Hassan El-Solh,1 Ali Al-Ahmari,1 Ashraf Khairy,1
Abdelmoneim Aldali,2 Samer Markiz,1 Khawar Siddiqui,1 Abdullah Al-Jefri1Low-dose cyclophosphamide (CY) is now considered the backbone of many of the conditioning regimens
used in patients with Fanconi anemia undergoing allogeneic stem cell transplantation (SCT). To reduce
the risk of rejection and improve results, CY is usually used in combination with other agents/modalities,
such as antithymocyte globulin (ATG), busulfan, radiation, and, more recently, fludarabine (Flu). In this study,
we used a uniform Flu-based conditioning regimen (ie, CY, Flu, ATG) in 26 pediatric patients with Fanconi
anemia undergoing SCT. The median patient age at the time of SCTwas 7.8 years, and the stem cell source
was an HLA-matched related donor in 19 patients and partially HLA-matched unrelated cord blood in 7 pa-
tients. The CY, Flu, ATG regimen was well tolerated overall, with a remarkably low incidence of graft-versus-
host disease and hemorrhagic cystitis. All 19 patients in the matched related donor group engrafted and were
alive and transfusion-independent at a median follow-up time of 19 months, compared with only 2 of 7 pa-
tients in the unrelated cord blood group.We conclude that the combination of CY, Flu, and ATG in the doses
used in this study is well tolerated, and that the proclaimed positive effect of adding Flu to the conditioning
regimens of patients with Fanconi anemia undergoing SCT is most pronounced in recipients of HLA-matched
related transplants. Its value in unrelated cord blood transplantation probably depends on other factors, such
as the degree of HLA matching and the cell dose.
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Fanconi anemia (FA) is highly prevalent in the
Kingdom of Saudi Arabia, due mainly to a high rate of
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6/j.bbmt.2011.08.015more than 120 allogeneic stem cell transplantations
(SCTs) have been performed in Saudi patients with
FA over the last 30 years at King Faisal Specialist Hos-
pital and Research Center, located in the capital city of
Riyadh [1-4]. The optimal conditioning regimen for
patients with FA is a matter of debate, but low-dose
cyclophosphamide (CY) has been accepted as the back-
bone of many regimens used in these patients. To
optimize results, CY has been traditionally used in
combination with other agents, such as busulfan,
antithymocyte globulin (ATG), and low-dose radia-
tion [1-9]. Fludarabine (Flu) has emerged over the
last 2 decades as a potent immunosuppressive agent
and is being increasingly used in conditioning
regimens for patients with FA and others [10-17]. In
this prospective study, we report our experience in
a single center using a uniform Flu-based conditioning
regimen in 26 patients with FA undergoing SCT.627
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This prospective study was approved by the
Research Advisory Council and the Ethics Committee
at King Faisal Specialist Hospital and Research Cen-
ter. Informed consent was obtained for all participants.Patients
Between October 2007 and August 2010, 26 pa-
tients with bone marrow failure due to FA were
referred to the Pediatric SCT Section at King Faisal
Specialist Hospital and Research Center for allogeneic
SCT. After referral, all patients had undergone chro-
mosomal breakage studies with mitomycin-C and/or
diepoxybutane to confirm the diagnosis of FA. All
patients underwent morphological and cytogenetic
examination of the bone marrow before SCT, and all
demonstrated some degree of bone marrow aplasia
with no myelodysplasia or leukemia. Cytogenetic
studies were normal in 20 patients, and 1 patient had
monosomy 7.
Thestudygroupcomprised11 femalesand15males,
with amedian age at the time of SCTof 7.8 years (range,
1.4-12.9 years). Nineteen patients received stem cells
from an HLA-matched related donor (group A), and
7 patients received partially HLA-matched unrelated
cord blood (group B). Engraftment was defined as the
first of 3 consecutive days with an absolute neutrophil
count of .500  106/L and was further confirmed by
donor–recipient chimerism studies at least once during
the first 3 months post-SCT, then at 6 months and
1 year post-SCT using a short tandem repeat method
on peripheral blood (granulocytes and lymphocytes). A
total of 16 short tandem repeat loci were analyzed.Conditioning Regimen
All patients were conditioned with CY 5 mg/kg i.v.
on days25,24,23, and –2; Flu 30mg/m2/dose i.v. on
days 26, 25, 24, 23, and 22; and rabbit ATG (Fre-
senius) 5 mg/kg i.v. on days 25, 24, 23, and 22.
Mesna was given to all patients during administration
of the conditioning regimen to prevent hemorrhagic
cystitis.GVHD Prophylaxis
GVHD prophylaxis was with cyclosporine at
standard doses. In addition, all patients undergoing
SCT before February 2009 (a total of 14 patients;
9 in group A and 5 in group B) received Fresenius
ATG 2.5 mg/kg i.v. on days 11, 13, 16, and 111;
the post-SCT ATG was later removed from the study
in view of the noted low incidence of GVHD. Cyclo-
sporine was tapered and discontinued by 6 months
post-SCT unless the patient developed GVHD. The
patients in group B also received methylprednisolone1 mg/kg i.v. from day 15 to day 120, which was
tapered over 2 weeks if no GVDH developed.
Donors
The 19 patients in group A received a transplant
from a related donor (16 from fully HLA-matched
siblings, 2 from fully HLA-matched fathers, and
1 from a single antigen HLA-mismatched sibling on
the A locus). All related donors had documented nega-
tive chromosomal breakage study results. Harvested
bone marrows were not manipulated. The median
CD341 cell count was 6.1  106/kg of recipient body
weight (range, 1.6-24.6  106/kg), and the median
dose of total nucleated cells (TNCs) was 3.5  108/kg
of recipient body weight (range, 0.9-69.3  108/kg).
The 7 patients in group B received partially HLA-
mismatched single unrelated cord blood units;
5 received single-antigen–mismatched units, and 2 re-
ceived 2-antigen–mismatched units. In these patients,
the median CD341 cell count was 3.2 105/kg (range,
0.3-6.5 105/kg), and the median total TNC dose was
8  107/kg (range, 3.6-17.3  107/kg).
Supportive Care
All patients were treated in high-efficiency partic-
ulate air–filtered rooms and were isolated until
engraftment. All patients received i.v. immunoglobu-
lin every 2 weeks at a dose of 500 mg/kg from day
24 up to day 190, as well as acyclovir 45 mg/kg/day
from day 23 to day 128. All patients also received
fluconazole therapy from day 0 until engraftment.
No prophylactic ganciclovir was given, and cytomega-
lovirus (CMV) status was monitored by weekly poly-
merase chain reaction analysis; preemptive therapy
was started in patients with positive results. All blood
products were leukocyte-filtered and irradiated. All
7 patients in group B and 16 of the 19 patients in group
A received granulocyte colony-stimulating factor
(GCSF) post-SCT.RESULTS
Engraftment
All 19 patients in group A engrafted. The median
time to engraftment was 13 days (range, 11-26 days).
The 3 patients who did not receive GCSF also
engrafted promptly, at 16, 12, and 16 days post-
SCT. The median time to achieve red blood cells
transfusion independence was 15 days (range, 9-46
days), and the median time to a self-sustained platelet
count of 20  109/L was 19 days (range, 14-47 days).
On last follow-up, 18 patients had 100% donor cells
in the myeloid line, and 1 patient had 80% donor cells;
in the lymphoid line, donor cell chimerism ranged
between 56% and 100% (median, 100%).
Table 1. Transplant Characteristics
Group A Group B
Stem cell source Matched related bone marrow Partially matched unrelated cord
Number of patients 19 7
Age at SCT, years, median (range) 9.1 (1.4-12.9) 7.7 (2-10)
CMV serology (+ recipient/+ donor) 16 3
CMV serology (+ recipient/2 donor) 3 4
CD34 cell dose, median (range) 6.1  106/kg (1.6-24.6  106/kg) 3.2  105/kg (0.3-6.5  105/kg)
TNC dose, median (range) 3.5  108/kg (0.9-69.3  108/kg) 8  107/kg (3.6-17.3  107/kg)
Conditioning regimen used CY, Flu, ATG CY, Flu, ATG
Patients alive and transfusion-independent, n 19 2
Acute GVHD, n 1 1
Chronic GVHD, n 1 1
HC, n 1 1
Veno-occlusive disease, n 1 0
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and 3 patients engrafted. The median time to
engraftment was 12 days (range, 11-26 days). How-
ever, only 2 of the patients who engrafted achieved
RBC transfusion independence (at 28 and 141 days)
and platelet transfusion independence (at 14 and
47 days), with the last chimerism analysis showing
100% donor cells (both myeloid and lymphoid).
The third patient developed secondary graft failure
at 7 months post-SCT, with a maximum donor cell
chimerism of 55% in the myeloid line and 74% in
the lymphoid line.GVHD
One patient in group A developed acute GVHD
grade 2 of the skin, and another patient had limited
chronic GVHD of the buccal mucosa. Both patients
responded to steroid therapy. In group B, 1 patient
developed acute GVHD grade 2 of the skin that
became chronic GVHD. The patient responded well
to steroid therapy, but eventually lost his graft, and
his GVHD abated.Figure 1. Overall survival of patients with FA undergoing SCT with
Flu-based conditioning.Regimen-Related Toxicities
Overall, the regimen was well tolerated. All
patients developed grade 3-4 mucositis requiring
i.v. analgesia. One patient from group A developed
self-limited veno-occlusive disease of the liver (max-
imum total bilirubin, 4.1 mg/dL). Hemorrhagic
cystitis developed in 2 patients (1 from group A
and 1 from group B); it was treated conservatively
with vigorous hydration and platelet transfusions,
and both patients responded. Six patients from
group A and 4 patients from group B developed
CMV infections based on positive CMV polymerase
chain reactions. All 10 patients received and re-
sponded to preemptive ganciclovir therapy; no
CMV disease was documented. To date, no second-
ary malignancies have been observed in either group
(Table 1).Follow-up and Causes of Death
All surviving patients who have an Absolute Neu-
trophil Count .500  106/L and are RBC/platelet
transfusion-independent with full or mixed chimerism
are considered progression-free. Accordingly, all pa-
tients in group A remain progression-free with a me-
dian follow-up of 19 months (range, 4.2-36 months);
this includes the patient with monosomy 7 before
undergoing SCT, who remains alive with 100% donor
chimerism. In group B, 2 patients remain progression-
free, at 33 months and 34 months post-SCT (Figures 1
and 2). The patient with secondary graft failure
remains alive at 29 months post-SCT, but is blood
product transfusion-dependent. All 4 patients with
primary graft failure in group B died, 1 due to sepsis
and organ failure at 2 months post-SCT. The other
3 patients underwent a second cord blood SCT after
conditioning with Fresenius ATG only (10 mg/kg/
Figure 2. Progression-free survival of patients with FA undergoing
SCTwith Flu-based conditioning.
630 Biol Blood Marrow Transplant 18:627-632, 2012M. Ayas et al.day for 4 days), at 1.5, 2, and 2.2 months after the first
SCT. One patient engrafted with 100% donor chime-
rism but died of sepsis 5.5 months after the second
SCT; the other 2 patients also died of sepsis without
engraftment at 2 weeks and 18 months after a second
SCT (Table 2).DISCUSSION
The optimal CY dose to use in the conditioning of
patients with FA undergoing SCT (ie, the lowest dose
that can ensure sustained engraftment with minimal
toxicity) has not been clearly established. In many cen-
ters, acceptable doses range between 20 and 80 mg/kg
[1-8]. To ensure adequate immune suppression and
reduce the risk of graft failure, the lower CY doses
are usually combined with other agents, such as
busulfan, ATG, Flu, and radiation. However, the use
of radiation in the conditioning has been implicated
in an increased risk of late malignancies in allogeneic
SCT recipients [18-21]. Therefore, there has been an
increased recent interest in the use of non–radiation-Table 2. Characteristics of Cord Blood Units in Patients with
Graft Failure
Unique
Patient
Number
Degree of HLA
Mismatch
CD34 Cell
Dose,
 105/kg
TNC
Dose,
 107/kg
Type of
Graft
Failure
1977 Two-antigen mismatch 0.5 5.8 Primary
2031 Two-antigen mismatch 3.5 8.0 Primary
2109 One-antigen mismatch 0.3 4.0 Secondary
2151 One-antigen mismatch 4.3 8.2 Primary
2244 One-antigen mismatch 1.4 3.65 Primarybased regimens in patients with FA [22]. This
approach is further supported by recent studies
demonstrating no survival advantage when radiation
was incorporated in the conditioning of these patients.
A Center for International Blood and Marrow Trans-
plant Research study published by Pasquini et al. [7]
compared outcomes in patients with FA undergoing
SCT from HLA-matched sibling donors with non–ir-
radiation-containing conditioning regimens (n 5 71)
and those with irradiation-containing regimens
(n 5 77), and found no significant difference in the
5-year probability of overall survival (78% vs 81%;
P 5 .61). A recent analysis at our institution compar-
ing outcomes in patients who received low-dose CY
(20 mg/kg) plus radiation conditioning (n 5 22) and
those who received a higher CY dose (60 mg/kg) but
with no radiation (n 5 34) proved the superiority of
the latter regimen (overall survival, 72.5% vs 96.9%;
P 5 .013) [3]. Despite the encouraging results,
however, a problem associated with the use of a higher
CY dose was a strikingly higher incidence of HC in the
latter group (23.5%; P 5 .04), which prompted us to
again lower the CY dosage to avoid this significant
complication.
Flu is a purine analog that inhibits DNA synthesis
by interfering with ribonucleotide reductase and DNA
polymerase. It is active against both dividing and
resting cells. Approved dosages range from 90 to
175 mg/m2 total dose, depending on the underlying
diagnosis and on the other drugs used in the prepara-
tory regimen [10-17,22]. Because of the specific
underlying genetic defects that make FA cells
unusually susceptible to alkylating agents, the use of
Flu in this setup seems particularly relevant. In fact,
numerous studies over the last 2 decades have
addressed the use of Flu in conditioning of patients
with FA undergoing HLA-matched related donor,
unrelated donor, and cord blood transplantations.
Stepensky et al. [10] recently reported a survival rate
of 83% in patients with FA undergoing allogeneic
SCT after conditioning with various Flu-containing
regimens, far superior to the 35% survival rate noted
in patients who received alternative regimens
(P 5 .002). The authors reported a relatively high
incidence of acute and chronic GVHD in the Flu
group (46% and 40%, respectively), but the donor
population in that study was mixed; 16 donors were
HLA-matched related, and 7 were HLA-matched
unrelated [10].
In our study, all patients underwent allogeneic
SCT using a uniform conditioning protocol of Flu,
low-dose CY, and rabbit ATG. At the time of this
report, all recipients of HLA-matched related trans-
plants are alive and transfusion-independent, with
a low incidence of GVHD and transplantation-
related complications. Furthermore, there have been
no cases of delayed graft failure, with a median
Biol Blood Marrow Transplant 18:627-632, 2012 631Flu-Based Conditioning for Saudi FA Patientsfollow-up of 19 months. This is in contrast to what we
foundwith our previous protocol using a higher dose of
CY (60mg/kg) with ATG, with 4 cases of delayed graft
failure occurring near the end of the first year. But in
contrast to the excellent outcomes in our HLA-
matched related transplant recipients, the outcomes
are dismal in our unrelated cord transplant recipients.
These results conform to those of a larger-scale study
by Gluckman et al. [23] that demonstrated an overall
poor outcome of unrelated cord blood SCT in patients
with FA, with a 3-year probability of survival of only
40%. However, the use of Flu was found to be a favor-
able factor for engraftment and survival (with a survival
rate of 50%). Another important factor associated with
a better outcome in that study was a higher CD34 cell
dose (.1.9  105/kg) [20,23]. In our study, the 2
unrelated cord blood transplant recipients with
durable engraftment received CD34 cell doses of
6.5  105/kg and 3.2  105/kg.
Patients with FA are usually considered at a greater
risk for GVHD, which may be more severe in these
patients because of the underlying DNA repair defect
[2,24,25]. The impact of GVHD on patients with FA
might not be limited to the early posttransplantation
period, because the lichen planus lesions associated
with chronic GVHD may predispose to squamous
cell carcinoma. Thus, chronic GVHD may be
considered a major risk factor for head and neck
carcinomas and late mortality in patients with FA
[18-21], and thus adequate GVHD prophylaxis in
patients with FA is paramount. In an effort to reduce
the incidence of GVHD, many groups now use
cyclosporine in addition to other agents, such as
mycophenolate mofetil, as GVHD prophylaxis
[26,27]. Some groups have used T cell depletion in
unrelated donor as well as HLA-matched related
donor SCT [12,28]. Many groups add ATG before
and after SCT with the aim of decreasing the
incidence of GVHD [3,5,29]. In the present study,
ATG post-SCT was initially incorporated in the pro-
tocol and was removed later, but its removal (at least
in the HLA-matched related donor group) did not
seem to affect hematopoietic recovery or the incidence
of acute and chronic GVHD. This suggests that the
ATG pre-SCT is probably sufficient to help reduce
the risk of GVHD.
The use of GCSF post-SCT in patients with FA
was recently associated with a worse outcome on uni-
variate analysis, suggesting that GCSF may contrib-
ute to a post-SCT immune deficiency syndrome
and to the risk of dying from transplantation-
related complications [11]. In the current study, 16
of 19 patients in the HLA-matched related transplant
group and all 7 patients of the unrelated cord blood
transplant group received GCSF post-SCT. Al-
though we cannot draw any conclusions related to
GCSF use in our cord blood recipients, our data inthe HLA-matched related recipient group do not
support this theory.
In conclusion, adding Flu to the conditioning reg-
imens for patients with FA seems to be more benefi-
cial in recipients of HLA-matched related transplants.
The value of Flu in conditioning regimens for unre-
lated cord blood transplant recipients is probably
masked by multiple other complicating factors, such
as cell dose and the degree of donor–recipient HLA
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